{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-311777","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2022-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.286021+00:00","generated_at":"2026-06-20T23:29:52.590957+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vor Biopharma enters into $125M at-the-market equity sales agreement with Stifel","bullets":["Agreement with Stifel for up to $125M of common stock sales in at-the-market offerings.","Stifel will receive a commission of 3.0% of gross sales proceeds from shares sold.","Replaces prior ATM agreement with Jefferies LLC, which was terminated on Dec 22, 2022.","Company has no obligation to sell shares; sales are at its sole discretion.","Prospectus supplement filed under existing Form S-3 registration statement (333-263541)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-311777","json":"https://secwatch.observer/filing/0001193125-22-311777.json","markdown":"https://secwatch.observer/filing/0001193125-22-311777.md","text":"https://secwatch.observer/filing/0001193125-22-311777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312522311777/0001193125-22-311777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312522311777/d402595d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:29:52.590957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4b05436c9b8038ff4aa5adab07e465edd44f77e","claim":"Vor Biopharma Inc. entered into At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated valued at up to $125.0 million (effective 2022-12-23).","evidence_excerpt":"On December 23, 2022, Vor Biopharma Inc. (the “ Company ”) entered into an At-the-Market Equity Offering Sales Agreement (the “ Agreement ”) with Stifel, Nicolaus & Company, Incorporated (“ Stifel ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), having an aggregate offering price of up to $125.0 million after the date of the Agreement through Stifel as its sales agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312522311777/0001193125-22-311777-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Stifel, Nicolaus & Company, Incorporated"},{"label":"Value","value":"up to $125.0 million"},{"label":"Effective","value":"2022-12-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}